ARISTOCRAT: A randomised controlled phase II trial of temozolomide with or without cannabinoids in patients with recurrent glioblastoma

ARISTOCRAT is a UK trial testing the use of the cannabis-based drug Sativex with the current chemotherapy treatment in treating patients with recurrent glioblastoma.

The trial is led by Professor Susan Short (Chief Investigator) at University of Leeds, in collaboration with CRCTU at the University of Birmingham and is funded by The Brain Tumour Charity and sponsored by the University of Birmingham.

When cancer comes back after treatment, doctors call it a recurrence or recurrent cancer. Only patients with recurrent disease are eligible for the ARISTOCRAT trial.

For more information on this, please visit the Cancer Research UK website on why some cancers come back.


Brain tumour patient Baljit Mehat (who sadly passed away this year) previously sat down with the ARISTOCRAT chief investigator, to ask some key questions. This video is for educational purposes only and is not intended to replace patient information for the trial. Patients should speak to a healthcare professional if they want more information about the trial.

Please note that the trials team cannot give individuals clinical advice. Patients and their families should contact their treating doctor to discuss trials for which they may be eligible.


Contact us

ARISTOCRAT Trial Office,
Cancer Research UK Clinical Trials Unit (CRCTU),
Institute of Cancer and Genomic Sciences,
University of Birmingham,
Edgbaston, Birmingham
B15 2TT 


Also in 'Aristocrat'